The following clinical trials are currently offered in Germany in this group.
5 matching trials
The CUPISCO study is investigating the use of targeted therapies or cancer immunotherapies versus chemotherapy in patients with cancer of unknown primary origin.
18 years and older · First line · Phase II
So-called high-risk tumors often progress very rapidly despite optimal treatment and are usually resistant to standard therapies. Immunotherapies and targeted drugs, such as the study drugs nivolumab and entinostat, offer new hope. Previous studies suggest that this combination may inhibit tumor growth in tumors with specific genetic characteristics. The goal of the INFORM2 study is to to investigate the efficacy of the combination therapy of nivolumab and entinostat in children and adolescents with treatment-resistant or recurrent high-risk tumors, and to compare whether the efficacy of this combination therapy differs in tumors with specific genetic alterations compared to those without these characteristics. Patients between the ages of 2 and 21 with a brain tumor or solid tumor classified as high-risk are eligible to participate. The tumor must either have a myc(n) amplification, a high mutation burden, or high PD-L1 expression—or none of these characteristics.
2–21 years · Relapsed / refractory · Phase I/II
Solid tumors are cancers that develop in organs such as the lungs, liver, or breast. When these tumors progress and no longer respond to standard therapies, novel drugs may be considered as additional treatment options. The goal of the IMA401-TCER study is to investigate the safety and tolerability of the new drug IMA401, which specifically targets certain cancer cells. Eligible participants include women and men aged 18 and older with advanced or metastatic solid tumors, including breast cancer, that no longer respond to standard therapies and exhibit a specific genetic profile (HLA-positive and MAGEA4/8).
18 years and older · Relapsed / refractory · Phase I
When malignant diseases of the blood system (leukemias, lymphomas) or tumors of other organs/tissues (solid tumors) in childhood do not respond to standard therapy (refractory) or recur (relapse), there are often significantly fewer established treatment regimens than in adults. Ponatinib, a tyrosine kinase inhibitor (TKI), is already approved for use in adults for certain forms of leukemia. The aim of this study is to investigate the safety and efficacy of ponatinib in children and adolescents with various types of cancer and to determine the optimal dose for treatment. Patients between the ages of 1 and 17 with previously treated, relapsed, or refractory leukemias, lymphomas, or solid tumors are eligible to participate.
1–17 years · Relapsed / refractory · Phase I/II
Rezatapopt is a novel, as-yet-unapproved drug that was developed specifically for the Y220C mutation in the TP53 gene. This gene controls cell growth; when a mutation occurs, the p53 protein loses its protective function, allowing cancer cells to multiply uncontrollably. Rezatapopt is intended to restore the function of the p53 protein. The PYNNACLE study is intended for patients with advanced solid tumors who have this specific genetic alteration (TP53 Y220C mutation). The goal of the study is to investigate the safety and efficacy of the investigational drug Rezatapopt. Eligible participants include women and men aged 18 and older, and, under certain conditions, adolescents between the ages of 12 and 17. The tumors must carry the TP53 Y220C mutation and must have already been treated with at least one prior cancer therapy.
12 years and older · Relapsed / refractory · Phase I/II
